These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2009-015837-55 Double-blind, 36 month, placebo-controlled trial of mifepristone on cognition in alcoholics 2016-06-24 due-trials
Reported results 2010-022184-35 A pragmatic randomised double-blind trial of Antipsychotic Treatment of very LAte-onset Schizophrenia-like psychosis: The ATLAS Trial 2016-12-14 due-trials
Reported results 2010-024551-82 OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH 22q11.2 DELETION SYNDROME (22qDS) 2013-03-22 due-trials
Reported results Terminated 2011-001088-28 Feasibility, efficacy and acceptability of injected buprenorphine as treatment for opiate users who persist in injecting illicit heroin through opiate maintenance treatment 2020-01-10 due-trials
Reported results Terminated 2011-005218-13 Rationalisation of antipsychotic drug use in older people, using [18F]-Fallypride PET 2016-02-04 due-trials
Reported results 2012-000517-37 A pilot study of Concerta XL in adult offenders with ADHD 2015-02-23 due-trials
Reported results 2012-002237-11 Effectiveness of Adaptive Opioid Agonist Maintenance Pharmacotherapy and Behavioural Therapy for Opioid Use Disorder. 2013-04-02 due-trials
Reported results Terminated 2013-000240-26 Cannabidiol as an add-on therapy in treatment-refractory psychotic disorders 2015-08-07 due-trials
Reported results 2013-000397-30 Minocycline in Alzheimer's disease efficacy trial:The MADE trial 2018-04-16 due-trials
Reported results Terminated 2013-002584-25 Naltrexone Enhanced Addiction Treatment (NEAT): A randomised controlled trial of the clinical and cost-effectiveness of extended-release naltrexone and oral naltrexone. 2017-04-21 due-trials
Reported results 2014-002639-32 A randomised, double-blind, placebo-controlled, parallel-group trial of Vitamin D supplementation compared to placebo in people presenting with their First Episode of psychosis (DFEND) Neuroprotection... 2019-12-20 due-trials
Reported results 2015-003413-26 Understanding the molecular basis for the use of adjunctive anti-inflammatory treatment in treatment resistant depression: a stratified, randomised, placebo-controlled, experimental medicine study usi... 2019-12-17 due-trials
Other 2016-001637-27 A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression. not-yet-due
Other 2016-001877-34 Improving understanding of Heroin Overdose Testing: diamorphine dose-escalation testing in a treated population not-yet-due
Other 2018-003573-97 A randomised, placebo controlled trial of psilocybin in treatment resistant depression: A feasibility study not-yet-due
Other 2018-004460-63 Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): An Open Label Randomised Controlled Trial of Injectable Depot Maintenance Buprenorphine versus Standard-Of-Care Oral Maintenance Opioid... not-yet-due
Other 2019-002106-52 CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease not-yet-due
Other 2019-003623-37 CANnabidiol for Parkinson’s Disease Psychosis not-yet-due
Other 2020-001056-17 A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia. not-yet-due